Cellusion Inc.

About Cellusion Inc.

Cellusion is a company focused on regenerating human potential through the development of next-generation regenerative medicine. Their mission is to contribute to the advancement of Japan's presence in the global healthcare industry by fostering innovative medical solutions. They aim to create a world with more freedom and more smiles.

Products & Services

Corneal Endothelial Regenerative Therapy using iPS Cells:Cellusion is developing a product targeting bullous keratopathy, a condition treated primarily by corneal transplantation. Their approach uses iPS cell-derived corneal endothelial substitute cells, which can be mass-produced, injected via a less invasive procedure, and delivered without the need for eye banks, addressing key bottlenecks in traditional corneal transplantation.

Specialties

iPS Cell Technology Corneal Endothelial Cell Therapy Regenerative Medicine for Bullous Keratopathy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 21000000 MR: - FA: 2.83 billion yen (21 million USD) FAN: 21000000	D: 2023-06-06 FD: 2023-06-06	10 investors

Series C Latest

2023-06-06

$21.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

羽

羽藤晋

President and CEO

坪

坪田

榛

榛村

Co-Founder of Cellusion Inc.

羽

羽藤晋

Representative Director and President of Celution Corporation

山

山中伸弥

松

松田直人

Former Representative of RegCell Corporation

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Cellusion Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised